文献速递前列腺癌

采用初段尿(非直肠指检)进行MyProstateScore 2.0检测的临床验证

Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine.
PubMed 文献 · J Urol · 2025-01-21

本研究在266例接受前列腺穿刺的男性中,验证了采用初段非直肠指检尿液进行MyProstateScore 2.0(MPS2)检测的性能。MPS2三种模型对GG≥2前列腺癌的AUC为71%至77%,高于PSA的57%和PCPTrc的62%。在检出超过90%的GG≥2癌症的前提下,MPS2可避免36%至42%的不必要穿刺,而PCPTrc仅避免13%。

要点

  • 初段非直肠指检尿液MPS2对GG≥2前列腺癌的AUC为71%至77%,PSA为57%,PCPTrc为62%。
  • 在检出超过90%的GG≥2癌症时,MPS2可避免36%至42%的不必要穿刺,PCPTrc为13%。
  • 既往穿刺阴性者中,MPS2可避免44%至53%的重复穿刺,PCPTrc仅2.6%。

核心结论

  • 采用初段尿液进行MPS2检测,在保持对GG≥2前列腺癌高敏感检出的同时,较PCPTrc显著提高了避免穿刺的比例。
  • 非直肠指检检测为PSA升高的男性减少影像和穿刺需求提供了一种便捷、客观且高度准确的检测选择。

研究设计与样本

  • 患者在接受穿刺前提供初段尿液,用于验证MPS2检测。
  • MPS2值通过既往验证的模型计算,模型仅依据纳入临床数据的范围不同:仅生物标志物(BA;无临床数据)、生物标志物加临床因素(BA+CF)、生物标志物加临床因素加前列腺体积(BA+CF+PV)。
  • 主要结局为穿刺病理诊断为GG≥2前列腺癌。
  • 队列纳入266名男性,中位PSA为6.6 ng/mL(IQR 4.9-9.1),其中103例(39%)穿刺诊断为GG≥2前列腺癌。

主要发现

  • GG≥2前列腺癌的AUC:PSA为57%,PCPTrc为62%,MPS2三种模型分别为71%、74%和77%。
  • 在检出超过90%的GG≥2癌症的检测策略下,MPS2检测可避免36%至42%的不必要穿刺,而PCPTrc为13%。
  • 在既往穿刺阴性的患者中,MPS2检测可避免44%至53%的重复穿刺,而PCPTrc仅为2.6%。

关键数值与推荐

  • MPS2模型包括BA、BA+CF和BA+CF+PV三种,对GG≥2前列腺癌的AUC分别为71%、74%和77%。
  • 在检出超过90%的GG≥2癌症条件下,MPS2可避免36%至42%的不必要穿刺,PCPTrc可避免13%。
  • 既往穿刺阴性患者中,MPS2可避免44%至53%的重复穿刺,PCPTrc可避免2.6%。

临床怎么用

  • 采用初段非直肠指检尿液进行MPS2检测,可便捷、客观地评估PSA升高男性GG≥2前列腺癌风险,减少不必要的影像和穿刺。
  • 对于既往穿刺阴性的患者,MPS2检测有助于减少重复穿刺。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of grade group (GG) ≥ 2 prostate cancer using post-digital rectal examination (DRE) urine. To improve ease of testing, we validated MPS2 using first-catch, non-DRE urine. MATERIALS AND METHODS: Patients provided first-catch urine before biopsy. MPS2 values were calculated using previously validated models differing only by extent of clinical data included biomarkers alone (BA; no clinical data), biomarkers and clinical factors (BA + CF), and biomarkers, clinical factors, and prostate volume (BA + CF + PV). The primary outcome was GG ≥ 2 cancer on biopsy. MPS2 performance and clinical consequences of testing were compared with PSA and the Prostate Cancer Prevention Trial risk calculator (PCPTrc). RESULTS: The cohort included 266 men with median PSA 6.6 ng/mL (IQR, 4.9-9.1) of whom 103 (39%) had GG ≥ 2 cancer on biopsy. The AUC for GG ≥ 2 cancer was 57% for PSA, 62% for PCPTrc, and 71%, 74%, and 77% for MPS2 models. Under a testing approach detecting > 90% of GG ≥ 2 cancers, MPS2 testing would have avoided 36% to 42% of unnecessary biopsies, as compared with 13% using the PCPTrc. In patients with a prior negative biopsy, MPS2 testing would have avoided 44% to 53% of repeat biopsies, as compared with only 2.6% using PCPTrc. CONCLUSIONS: Using first-catch urine, MPS2 meaningfully improved the proportion of biopsies avoided relative to PCPTrc while maintaining highly sensitive detection of GG ≥ 2 cancer. Non-DRE testing provides a convenient, objective, and highly accurate testing option to reduce the need for imaging and biopsy in men with elevated PSA.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tosoian JJ, Zhang Y, Meyers JI, et al. Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine. J Urol. 2025. PMID: 39836866. doi:10.1097/JU.0000000000004421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。